Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Q3 2025 value amounting to $860.2 million.

  • Amphastar Pharmaceuticals' Total Non-Current Liabilities rose 882.32% to $860.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $860.2 million, marking a year-over-year increase of 882.32%. This contributed to the annual value of $824.2 million for FY2024, which is 312.02% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Total Non-Current Liabilities of $860.2 million as of Q3 2025, which was up 882.32% from $830.1 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Total Non-Current Liabilities registered a high of $933.8 million during Q3 2023, and its lowest value of $181.4 million during Q1 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Total Non-Current Liabilities value was $759.4 million (recorded in 2024), while the average stood at $536.0 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 35036.85% in 2023, then crashed by 1534.93% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $210.4 million in 2021, then decreased by 5.51% to $198.8 million in 2022, then soared by 328.03% to $850.8 million in 2023, then decreased by 3.12% to $824.2 million in 2024, then increased by 4.37% to $860.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $860.2 million for Q3 2025, versus $830.1 million for Q2 2025 and $850.6 million for Q1 2025.